2025 could be a transformative year for aTyr Pharma Inc. (ATYR), as anticipated key catalysts have the potential to significantly shape its trajectory.
This clinical-stage biotechnology company is focused on developing new therapies for fibrosis and inflammation. Its lead therapeutic candidate is Efzofitimod, under development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can lead to chronic inflammation and progressive scarring, or fibrosis, of the lungs.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com